Produits & Services Relations Investisseurs
Cerep ? News Evénéments & Conférences Contacts Téléchargements FAQs
Cerep home
Your data onlineCatalog online
Home > Products & Services> Pharmacology & ADME-Tox > Assay platform > Kinase Assay Platform
Kinases as drug discovery targets

Following GPCRs, kinases comprise the most interesting target family in drug discovery 1. Kinases are a large family of 518 members classified in two sub-families (tyrosine and serine-threonine kinases), mediating a wide spectrum of actions via signal transduction pathways 2.
Kinases are involved in therapeutic areas of high interest including cancer, inflammation and diabetes. The last five years have seen eight anticancer kinase inhibitors receiving FDA approval, increasing recognition of kinases as a vital drug target class 3.
Cerep uses a unique, high throughput format – HTRF® – for all kinase testing allowing comparison across kinases and across types of experiments.

Cerep’s unique and versatile kinase platform is optimized to support drug discovery programs:
 Reproducible and robust allowing HTS, MTS and profiling
 Rapid turnaround time
 Highly diverse kinase panel
 Competitive cost
 Powerful tool for lead generation
 New kinase assays continuously added: 151 kinases are available as of January 1, 2008

 Access to Catalog Online
 Download Area
1 Cohen P. (2002), Nature Reviews/Drug Discovery, 1: 309-315
2 Manning G. et al. (2002), Science, 298:1912-1934.
3 Wai Lang Chu, October 9, 2006:
HTRF® is a trademark of CisBio International
© Kinome original design by Cell Signaling technology –

Pharmacology & ADME-Tox
In vitro pharmacology
Assay platforms
Global profiling services
Kinase assay platform
Functional GPCR platform
Binding assay platform
Custom assay development
Assay catalog
BioPrint® services

English :: Accueil :: Plan du site :: Mentions légales :: Crédits